Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Gomez-Roca

Showing results (11-20 of 77) with videos related to

Pageof 8
Sort By:
Frontiers in Medicine|August 14, 2024
A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature reviewFrançois Poumeaud, Marion Jaffrelot, Carlos Gomez-Roca, et al.
International Journal of Cancer|November 24, 2020
Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer CenterGhassan Al Darazi, Elodie Martin, Jean-Pierre Delord, et al.
Investigational New Drugs|December 15, 2018
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancerAlexandra Leary, Christophe Le Tourneau, Andrea Varga, et al.
Investigational New Drugs|May 30, 2018
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumorsSandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2011
Tumour growth rates and RECIST criteria in early drug developmentCarlos Gomez-Roca, Serge Koscielny, Vincent Ribrag, et al.
Onkologie|June 19, 2013
Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trialsAntonin Levy, Carlos Gomez-Roca, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2011
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issuesCharles Ferté, Angelo Paci, Meriem Zizi, et al.
Cancer Chemotherapy and Pharmacology|October 24, 2018
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancerNicolas Martin, Nicolas Isambert, Carlos Gomez-Roca, et al.
Melanoma Research|September 1, 2017
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combinationAmélie Aboudaram, Anouchka Modesto, Léonor Chaltiel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay, Carlos Gomez-Roca, L Rhoda Molife, et al.
Pageof 8

Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Frontiers in Medicine|August 14, 2024
A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature reviewFrançois Poumeaud, Marion Jaffrelot, Carlos Gomez-Roca, et al.
International Journal of Cancer|November 24, 2020
Improving patient selection for immuno-oncology phase 1 trials: External validation of six prognostic scores in a French Cancer CenterGhassan Al Darazi, Elodie Martin, Jean-Pierre Delord, et al.
Investigational New Drugs|December 15, 2018
Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancerAlexandra Leary, Christophe Le Tourneau, Andrea Varga, et al.
Investigational New Drugs|May 30, 2018
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumorsSandrine Hiret, Nicolas Isambert, Carlos Gomez-Roca, et al.
European Journal of Cancer (Oxford, England : 1990)|July 19, 2011
Tumour growth rates and RECIST criteria in early drug developmentCarlos Gomez-Roca, Serge Koscielny, Vincent Ribrag, et al.
Onkologie|June 19, 2013
Clinical benefit for patients with non-small cell lung cancer enrolled in phase I trialsAntonin Levy, Carlos Gomez-Roca, Christophe Massard, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2011
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issuesCharles Ferté, Angelo Paci, Meriem Zizi, et al.
Cancer Chemotherapy and Pharmacology|October 24, 2018
Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancerNicolas Martin, Nicolas Isambert, Carlos Gomez-Roca, et al.
Melanoma Research|September 1, 2017
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combinationAmélie Aboudaram, Anouchka Modesto, Léonor Chaltiel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2011
Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?Sophie Postel-Vinay, Carlos Gomez-Roca, L Rhoda Molife, et al.
Pageof 8